Cardiff Oncology, Inc.
For the period ended Jun 30, 2026. Filed Aug 11, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 11, 2026
CRDF$0.80+5.3%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements of Operations
(in thousands, except per share amounts)
| Three Months Ended June 30, | Six Months Ended June 30, | |||
|---|---|---|---|---|
| 2026 | 2025 | 2026 | 2025 | |
| Royalty revenues | $104 | $121 | $145 | $230 |
| Costs and expenses: | ||||
| Research and development | 5,915 | 11,580 | 12,680 | 22,057 |
| Selling, general and administrative | 3,804 | 3,318 | 9,930 | 7,332 |
| Total operating expenses | 9,719 | 14,898 | 22,610 | 29,389 |
| Loss from operations | (9,615) | (14,777) | (22,465) | (29,159) |
| Other income (expense), net: | ||||
| Interest income | 382 | 835 | 888 | 1,776 |
| Other income (expense), net | 1 | (1) | — | 6 |
| Total other income (expense), net | 383 | 834 | 888 | 1,782 |
| Net loss | (9,232) | (13,943) | (21,577) | (27,377) |
| Preferred stock dividend payable on Series A Convertible Preferred Stock | (6) | (6) | (12) | (12) |
| Net loss attributable to common stockholders | $(9,238) | $(13,949) | $(21,589) | $(27,389) |
| Net loss per common share — basic and diluted | $(0.14) | $(0.21) | $(0.32) | $(0.41) |
| Weighted-average shares outstanding — basic and diluted | 68,397 | 66,526 | 68,373 | 66,525 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.